๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Jiangxi
Clinical trial register · China

Clinical Trials in Jiangxi, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Jiangxi

10 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
NCT07431060Langerhans Cell Histiocytosis (LCH)
West China Second University Hospital
Not applicable
120
Chengdu, Guiyang, Hefei, Jiangxi, Kunming, Nanning, รœrรผmqi, Xi'an
2026-02-13
Not yet open
Study on the Intervention Effect of Denosumab on High-Risk Patients With Osteoporotic Fractures in Type 2 Diabetes
NCT07063797Type 2 Diabetes, Osteoporosis, Fractures
Peking Union Medical College Hospital
Not applicable
358
Beijing, Huai'an, Jiangxi, Kunshan
2026-02-01
Recruiting
Synthetic PET From CT Improves Precision Diagnosis and Treatment of Lung Cancer: a Prospective, Observational, Multicenter Study
NCT07243873Lung Cancer, PET-CT
Shanghai Pulmonary Hospital, Shanghai, China
Observational
10,000
Zunyi, Jiangxi, Shanghai, Ningbo
2025-12-01
Recruiting
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
NCT06959095Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline
Phase 3
981
Changsha, Chengdu, Guangzhou, Hangzhou, Jiangmen, Jiangxi, Mianyang, Qingyuan
2025-06-20
Not yet open
Efficacy and Safety of Electroacupuncture on Lumbar Disc Herniation with Radiculopathy
NCT06611332Lumbar Disc Herniation, Radiculopathy Lumbar
Jiangxi University of Traditional Chinese Medicine
Not applicable
170
Jiangxi
2024-10-15
Recruiting
A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer
NCT06203210Small Cell Lung Cancer
Daiichi Sankyo
Phase 3
540
Beijing, Changchun, Changsha, Chengdu, Chongqing, Haerbin, Hangzhou, Jiangxi
2024-05-21
Recruiting
ML Models Predicting Cycloplegic Refractive Error Based on Non-Cycloplegic Parameters in Myopic Adults
NCT07690813Refractive Errors, Cycloplegic Refraction, Accommodation
Second Affiliated Hospital of Nanchang University
Observational
2,500
Jiangxi
2023-10-03
Recruiting
The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
NCT07272343Type 2 Diabetes Mellitus (T2DM), Semaglutide, Caloric Restriction
Second Affiliated Hospital of Nanchang University
Phase 4
100
Jiangxi
2023-02-10
Recruiting
Prophylactic Irradiation to the Contralateral Breast for BCAs Patients
NCT04960839Breast Cancer
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
323
Jiangxi, Shanghai, Hangzhou
2023-01-01
Active, closed
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
NCT05502237Non-small Cell Lung Cancer
Gilead Sciences
Phase 3
1,021
Chengdu, Chongqing, Deyang, Fuzhou, Guangzhou, Hangzhou, Jiangxi, Jinan
2022-10-12
Rows per page Showing 1–10 of 10
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/city/jiangxi

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 10 of those studies with a site in Jiangxi.

How many clinical trials are recruiting in Jiangxi?

7 of the 10 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 2 have not yet opened recruitment, 1 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Jiangxi), 10 studies
PhaseStudiesRecruitingShare
Not applicable4240%
Phase 33230%
Observational2220%
Phase 41110%

Most active sponsors

Lead sponsors with the most studies (Jiangxi)
Lead sponsorStudiesRecruiting
Second Affiliated Hospital of Nanchang University22
Daiichi Sankyo11
Gilead Sciences10
GlaxoSmithKline11
Jiangxi University of Traditional Chinese Medicine10
Peking Union Medical College Hospital10
Second Affiliated Hospital, Zhejiang University, School of Medicine11
Shanghai Pulmonary Hospital, Shanghai, China11
West China Second University Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.